HTG Molecular, Spanish Institute Sign Cancer Tool Development Deal

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed a research agreement with Spain’s Instituto Valenciano de Oncología (IVO) to develop and validate a breast cancer recurrence risk score using the company’s technology.

Under the terms of the deal, the partners will use HTG’s EdgeSeq Oncology biomarker panel to develop a breast cancer recurrence risk score based on genes differentially expressed in patients with low and high risk of recurrence. Additional terms were not disclosed.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
.

Be the first to comment

Leave a Reply

Your email address will not be published.


*